Case Details
- Citation: [2022] SGHC 75
- Title: Mytsyk, Viktoriia v Med Travel Pte Ltd and another
- Court: High Court of the Republic of Singapore (General Division)
- Date of Decision: 31 March 2022
- Originating Summons: HC/OS 987/2021
- Judges: Mavis Chionh Sze Chyi J
- Hearing Dates: 13 January 2022, 25 February 2022
- Judgment Reserved: Yes (judgment reserved after 25 February 2022)
- Plaintiff/Applicant: Mytsyk, Viktoriia (“Ms Mytsyk”)
- Defendants/Respondents: (1) Med Travel Pte Ltd (“Med Travel”) (2) Amunugama Anushka Bandara (“Mr Anushka”)
- Legal Area: Companies — Statutory derivative action
- Statutory Provision Referenced: s 216A of the Companies Act (Cap 50, 2006 Rev Ed) (“Companies Act”)
- Other Statutory References (as reflected in metadata): Companies Act (multiple references in metadata)
- Key Procedural Posture: Application for leave under s 216A to commence a statutory derivative action in the name and on behalf of the company
- Representation: Ms Mytsyk represented by counsel; Mr Anushka acted in person
- Judgment Length: 49 pages; 15,748 words
- Related Proceedings Mentioned: HC/S 1247/2019 (“S 1247”)—a civil suit involving allegations including ownership and beneficial interest in Med Travel and Health & Help Pte Ltd
Summary
This case concerns an application by a shareholder, Ms Viktoriia Mytsyk, for leave under s 216A of the Companies Act to bring a statutory derivative action on behalf of Med Travel against its director, Mr Anushka. The proposed derivative action alleged multiple breaches of directors’ duties, including misappropriation of company funds, forgery of documents, unlawful diversion of income, unlawful prevention of business, misuse of company funds for personal expenses, and negligence leading to penalties for late GST submissions. The application also sought an order that Med Travel indemnify Ms Mytsyk for reasonable legal fees and disbursements.
The High Court (Mavis Chionh Sze Chyi J) focused on two central statutory gateways: (1) whether Ms Mytsyk had locus standi to bring the application (ie, whether she fell within the statutory definition of a “complainant” and/or was a “proper person”); and (2) whether the proposed derivative action satisfied the leave requirements under s 216A(3), including the “good faith” requirement and whether the action “appears prima facie to be in the interests of the company.” The court also addressed arguments that the application was brought for collateral purposes, given the broader context of matrimonial and related civil litigation between the parties.
What Were the Facts of This Case?
Ms Mytsyk and Mr Anushka were previously married and lived together for several years with children. Their relationship deteriorated, and Ms Mytsyk commenced divorce proceedings in August 2019. Shortly thereafter, she also initiated a civil suit, HC/S 1247/2019 (“S 1247”), against Mr Anushka and Med Travel. In S 1247, Ms Mytsyk and co-plaintiffs sought declarations, among other things, that Mr Liaskovskyi was the true legal and beneficial owner of both Med Travel and another company, Health & Help Pte Ltd, in which Ms Mytsyk was the sole shareholder and director on record.
Med Travel was incorporated on 5 June 2012 and, at incorporation, Mr Anushka was its sole shareholder and director on record. On 20 November 2013, Mr Anushka transferred 50% of the shares to Mr Liaskovskyi. On 13 June 2016, Mr Liaskovskyi transferred that 50% shareholding to Ms Mytsyk. Ms Mytsyk was appointed a director of Med Travel on 7 June 2018. While these documentary facts were not disputed, the parties’ narratives diverged sharply.
Ms Mytsyk’s position was that Mr Anushka acted merely as a “nominee shareholder and director” and held Med Travel’s shares on behalf of Mr Liaskovskyi, who she alleged was the true beneficial owner. She alleged that Mr Anushka should have transferred 100% of the shares to Mr Liaskovskyi in November 2013 rather than only 50%, and that Mr Anushka forged Mr Liaskovskyi’s signature on the share transfer documents. She further alleged that Mr Anushka forged documents relating to her appointment as a director, although she later indicated she consented to and/or ratified that appointment.
Mr Anushka denied these allegations. He asserted that Med Travel formed part of a “Family Business” together with Health & Help, and that he and Ms Mytsyk were equal partners in that family business. He claimed there was a “Mutual Understanding” governing how the companies would be run and how income and family expenses would be managed. Against this background, the present application under s 216A was brought as a mechanism to pursue alleged wrongdoing by Mr Anushka in his capacity as director of Med Travel.
What Were the Key Legal Issues?
The first key issue was locus standi: whether Ms Mytsyk was a “complainant” within the meaning of s 216A(1) of the Companies Act, and whether she could be regarded as a “proper person” to bring the derivative action under s 216A read with the relevant provisions on standing. Mr Anushka argued that Ms Mytsyk failed to identify the capacity in which she brought the application and could not show standing as a shareholder under s 216(1)(a) nor satisfy the “proper person” requirement under s 216(1)(c).
The second key issue was whether the statutory leave requirements were met. Under s 216A(3), the court had to consider, among other things, whether the applicant had acted in good faith and whether the proposed derivative action “appears prima facie to be in the interests of the company.” Mr Anushka contended that the application was not genuinely directed to the company’s interests but was instead driven by collateral purposes, including the parties’ ongoing matrimonial dispute and the broader litigation in S 1247.
Accordingly, the court had to evaluate the substance of the proposed claims—at least at a prima facie level—while also assessing the applicant’s motivation and the overall fit of the derivative action within the statutory framework.
How Did the Court Analyse the Issues?
On locus standi, the court rejected the submission that Ms Mytsyk had failed to identify her capacity. The judgment indicates that the court did not accept that the application was procedurally defective in the manner alleged. Instead, it treated Ms Mytsyk’s supporting affidavits and the way the application was framed as sufficient to show that she was bringing the application as a shareholder seeking to enforce the company’s rights against its director. The court’s approach reflects the statutory purpose of s 216A: to provide a structured route for minority enforcement where the company itself is unwilling or unable to act.
Turning to the “good faith” requirement, the court examined the allegations in detail. Ms Mytsyk’s proposed derivative action pleaded a series of alleged director breaches. These included: (a) misappropriation of company funds by withdrawing approximately $477,000 from Med Travel’s bank accounts around 1 October 2019; (b) forgery of “financial documents”; (c) causing Med Travel to incur an unaffordable debt by purchasing a property at Novena Royal Square (“the Property”), allegedly knowing the company lacked sufficient funds to purchase and service the financing charges; (d) unlawful diversion of income due to Med Travel from Murex to Mr Anushka’s own company, A B Capital Pte Ltd; (e) unlawful prevention of Med Travel from carrying on business; (f) misuse of Med Travel funds for personal expenses, including legal fees incurred in the divorce proceedings and unauthorised transportation costs; and (g) negligence causing Med Travel to incur penalties due to late GST submissions.
The court also considered an additional allegation concerning the Property. Ms Mytsyk argued that Mr Anushka misused Med Travel’s overdraft facilities by drawing on them to meet monthly mortgage payments, leaving the company overdrawn by about $80,000 and allegedly at risk of further debt. She further alleged that after renting out the Property against her objections, Mr Anushka procured rent to be paid into his personal account rather than Med Travel’s account, and that even after she prevailed on one occasion to have rent paid into Med Travel’s account, he allegedly reverted to diverting rent to himself on multiple occasions.
In response, Mr Anushka’s position was not merely a denial of wrongdoing but also a broader narrative that the parties operated a family business with shared understanding and mutual arrangements. This narrative was relevant to the court’s assessment of good faith and collateral purpose. The court therefore scrutinised whether the derivative action was being pursued as a genuine attempt to vindicate Med Travel’s corporate interests or whether it was being used as an extension of the matrimonial dispute and the litigation in S 1247.
In analysing “good faith,” the court applied the principles under s 216A(3)(b) and (c). While the judgment extract provided in the prompt is truncated, the structure of the judgment (as reflected in the headings) shows that the court separately addressed: (1) the applicable principles; (2) the meaning and content of the “good faith” requirement; (3) whether the applicant satisfied that requirement; and (4) whether the action was brought for a collateral purpose. The court also examined the “prima facie interests of the company” requirement under s 216A(3)(c), again treating it as a distinct statutory gateway.
Importantly, the court appears to have treated the existence of related litigation (S 1247) as relevant context rather than determinative. The court considered the dispute in S 1247, including the allegation of misappropriation of company funds, forgery of financial documents, the property purchase, diversion of income, prevention of business, misuse of funds for personal expenses, and GST-related penalties. This suggests the court was careful to avoid conflating the derivative action with the declaratory and ownership-focused claims in S 1247, while still recognising that the same factual matrix could inform the assessment of whether the derivative action was genuinely in the company’s interests.
On the collateral purpose argument, the court addressed Mr Anushka’s contention that the application was not brought for the company’s benefit. The judgment headings indicate that the court specifically considered whether Ms Mytsyk was bringing the intended derivative action for a collateral purpose, and then reached a conclusion on good faith. The court’s reasoning would have required it to weigh the seriousness and coherence of the pleaded director breaches against the surrounding circumstances, including the parties’ relationship and the ongoing disputes.
Finally, the court assessed whether the proposed derivative action “appears prima facie to be in the interests of the company.” This is not a full trial on the merits; rather, it is a threshold evaluation. The court’s analysis would have involved considering whether the alleged breaches, if established, would plausibly benefit the company (for example, by recovering misappropriated funds, reversing unlawful diversions, or addressing conduct that undermined the company’s ability to carry on business). The court’s conclusion on this point would determine whether leave should be granted despite the contested narratives and the risk of the derivative action being used as leverage in personal disputes.
What Was the Outcome?
The High Court granted leave under s 216A for Ms Mytsyk to bring the statutory derivative action on behalf of Med Travel against Mr Anushka. The practical effect is that Ms Mytsyk was permitted to commence proceedings in the company’s name, thereby enabling the company’s claims against its director to be pursued through a minority enforcement mechanism.
The decision also addressed the ancillary request for indemnification of reasonable legal fees and disbursements. While the prompt does not include the final operative orders in full, the structure of the application indicates that the court considered whether such indemnity was appropriate in the circumstances, consistent with the statutory scheme and the court’s discretion in derivative proceedings.
Why Does This Case Matter?
This case is significant for practitioners because it illustrates how the Singapore courts approach the statutory leave requirements for derivative actions under s 216A, particularly the “good faith” and “prima facie interests of the company” gateways. The judgment demonstrates that courts will not treat derivative actions as purely formalistic; instead, they will examine the applicant’s motivation and the coherence of the pleaded director breaches in light of the surrounding context.
For minority shareholders, the decision provides practical guidance on how to frame a derivative action application. Applicants should clearly establish standing, demonstrate good faith, and provide sufficient factual basis for the allegations such that the proposed action appears prima facie to benefit the company. For directors and majority controllers, the case also underscores that collateral purpose arguments must be supported by persuasive reasoning tied to the statutory criteria, not merely by pointing to parallel disputes.
More broadly, the case contributes to the developing jurisprudence on statutory derivative actions in Singapore. It sits alongside earlier High Court decisions interpreting s 216A and related provisions, and it reinforces the court’s role in balancing two competing concerns: preventing abuse of the derivative mechanism while ensuring that legitimate corporate claims are not stifled by internal deadlock or unwillingness to sue.
Legislation Referenced
- Companies Act (Cap 50, 2006 Rev Ed), s 216A (statutory derivative action) [CDN] [SSO]
- Companies Act (Cap 50, 2006 Rev Ed), s 216 (standing concepts including “complainant” and “proper person” as referenced in the judgment) [CDN] [SSO]
Cases Cited
- [2014] SGHC 147
- [2015] SGHC 14523
- [2019] SGHC 180
- [2022] SGHC 75
Source Documents
This article analyses [2022] SGHC 75 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.